Furthermore, dedicated heart failure trials including Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial [126] and Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) trial [127] showed no significant reduction in heart failure hospitalizations, while the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study demonstrated that liraglutide had no impact on mortality or hospitalizations in established heart failure patients [128]. Here, GCG is linked to heart failure.